Take Homes in Colorectal Cancer

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the IMPROVE trial, which she said showed significant results in terms of the length of PFS on treatment with an intermittent panitumumab plus FOLFIRI strategy.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the TRIPLETE trial, which she said showed no improvement when irinotecan was added to FOLFOX panitumumab in patients with mostly unresectable RAS and BRAF wild-type left-sided metastatic colorectal cancer.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the STRATEGIC-1 trial, which she said validates a common initial treatment strategy for patients with RAS and BRAF wild-type metastatic colorectal cancer.

In this video Michael Cecchini, MD discussed study presented at ASCO that "puts to rest" whether asymptomatic primary tumors in patients with metastatic colorectal cancer should be resected.

In this video, Michael Cecchini, MD, discussed a late-breaking abstract evaluating FOLFOXIRI plus panitumumab vs. mFOLFOX6 plus panitumumab as initial treatment of unresectable RAS and BRAF wild-type metastatic colorectal cancer.

In this video, Michael Cecchini, MD, discussed the late-breaking phase 2 study presented at ASCO Annual Meeting on single-agent dostarlimab for patients with mismatch repair-deficient or microsatellite instability high rectal cancer.

In this video, Michael Cecchini, MD, discussed the late-breaking phase 3 PARADIGM trial presented at an ASCO Annual Meeting plenary session.

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed four colorectal cancer presentations from ASCO Annual Meeting, including the phase 3 TRIPLETE study, phase 3 STRATEGIC-1 study, IMPROVE study and late-breaking PARADIGM trial.

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed the importance of biomarker testing and the challenges involved.

In this video, Howard S. Hochster, MD, FACP, discusses a late-breaking abstract on the phase 3 PARADIGM trial, which looked at panitumumab vs. bevacizumab as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.